Free Equity Delivery
Flat ₹10 per Trade in Intraday & F&O
Gland Pharma IPO is a book build issue of ₹6,479.55 crores. The issue is a combination of fresh issue of 0.83 crore shares aggregating to ₹1,250.00 crores and offer for sale of 3.49 crore shares aggregating to ₹5,229.55 crores.
Gland Pharma IPO bidding started from Nov 9, 2020 and ended on Nov 11, 2020. The allotment for Gland Pharma IPO was finalized on Nov 17, 2020. The shares got listed on BSE, NSE on Nov 20, 2020.
Gland Pharma IPO price band is set at ₹1500.00 per share . The lot size for an application is 10. The minimum amount of investment required by an retail is ₹14,900 (10 shares). The lot size investment for sNII is 14 lots (140 shares), amounting to ₹2,10,000, and for bNII, it is 67 lots (670 shares), amounting to ₹10,05,000.
Citigroup Global Markets India Pvt.Ltd. is the book running lead manager and MUFG Intime India Pvt.Ltd. is the registrar of the issue.
Refer to Gland Pharma IPO RHP for detailed Information.
| IPO Date | November 9, 2020 to November 11, 2020 |
| Listing Date | November 20, 2020 |
| Face Value | ₹1 per share |
| Issue Price Band | ₹1490 to ₹1500 per share |
| Issue Price Final | ₹1500 per share |
| Lot Size | 10 Shares |
| Sale Type | Fresh Capital-cum-Offer for Sale |
| Total Issue Size | 4,31,96,968 shares (aggregating up to ₹6,479.55 Cr) |
| Fresh Issue | 83,33,333 shares (aggregating up to ₹1,250.00 Cr) |
| Offer for Sale | 3,48,63,635 shares of ₹1 (aggregating up to ₹5,229.55 Cr) |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE, NSE |
| Share Holding Pre Issue | 15,49,49,490 shares |
| Share Holding Post Issue | 16,32,82,823 shares |
Gland Pharma IPO offers total 4,31,96,968 shares. Out of which 2,15,98,483 (50.00%) allocated to QIB, 86,39,394 (20.00%) allocated to QIB, 64,79,546 (15.00%) allocated to NII, 1,51,18,939 (35.00%) allocated to RII and 1,29,59,089 (30.00%) allocated to Anchor investors.
| Investor Category | Shares Offered | Maximum Allottees |
|---|---|---|
| QIB Shares Offered | 2,15,98,483 (50.00%) | NA |
| − Anchor Investor Shares Offered | 1,29,59,089 (30.00%) | NA |
| − QIB (Ex. Anchor) Shares Offered | 86,39,394 (20.00%) | NA |
| NII (HNI) Shares Offered | 64,79,546 (15.00%) | NA |
| Retail Shares Offered | 1,51,18,939 (35.00%) | 15,11,893 |
| Total Shares Offered | 4,31,96,968 (100.00%) |
Gland Pharma IPO opens on November 9, 2020, and closes on November 11, 2020.
| IPO Open Date | Mon, Nov 9, 2020 |
| IPO Close Date | Wed, Nov 11, 2020 |
| Tentative Allotment | Tue, Nov 17, 2020 |
| Initiation of Refunds | Wed, Nov 18, 2020 |
| Credit of Shares to Demat | Thu, Nov 19, 2020 |
| Tentative Listing Date | Fri, Nov 20, 2020 |
| Cut-off time for UPI mandate confirmation | 5 PM on Wed, Nov 11, 2020 |
Investors can bid for a minimum of 10 shares and in multiples thereof. The following table depicts the minimum and maximum investment by Individual Investors (Retail) and HNI in terms of shares and amount.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 10 | ₹15,000 |
| Retail (Max) | 13 | 130 | ₹1,95,000 |
| S-HNI (Min) | 14 | 140 | ₹2,10,000 |
| S-HNI (Max) | 66 | 660 | ₹9,90,000 |
| B-HNI (Min) | 67 | 670 | ₹10,05,000 |
Note : The value will be calculated using Equity Dilution = Share Holding Pre Issue - Share Holding Post Issue
Gland Pharma Ltd, the Hyderabad-based company is one of the fastest-growing generic injectable companies. It manufactures a diversified range of high-quality complex injectables. The company offers products like sterile injectables, oncology, and ophthalmics, complex injectables (peptides, suspensions, hormonal products, long-acting injectables), NCE-1s, First-to-File products, etc.
The company follows a B2B model to sell its products in more than 60 countries including the US, Canada, Australia, India, Europe, etc. Leading pharma companies i.e. Sagent Pharmaceuticals, Apotex Inc. Athnex Pharmaceutical Division, LLC, Fresenius Kabi USA, LLC, etc. are some of the key customers.
It has 7 robust manufacturing units in India comprising 4 finished formulations facilities, 22 production lines, and 3 APIs.
Company Strengths
| Particulars | For the year/period ended (Rs in million) | |||
|---|---|---|---|---|
| 30-June-20 | 31-Mar-20 | 31-Mar-19 | 31-Mar-18 | |
| Total Assets | 46,912.65 | 40,860.39 | 35,235.49 | 29,294.68 |
| Total Revenue | 9,162.89 | 27,724.08 | 21,297.67 | 16,716.82 |
| Profit After Tax | 3,135.90 | 7,728.58 | 4,518.56 | 3,210.51 |
The Company Gland Pharma IPO proposes to utilise the Net Proceeds from the Issue towards the following objects:
| S.No. | Objects of the Issue | Expected Amount (₹ in crores) |
|---|---|---|
| 1 | Funding incremental working capital requirements of our Company | 769.50 |
| 2 | Funding capital expenditure requirements of our Company | 168.00 |
| 3 | General corporate purposes | 286.47 |
[Dilip Davda] No doubt that currently, the pharma sector is attracting investors following COVID-19 pandemic and the search of remedies for it globally. This company has posted good performance for the last three fiscals and spectacular numbers for Q1 of FY21, but will it sustain going forward is a major concern in the present context of negative sentiment for China connections globally. Based on P/BV and P/E parameters, the issue appears fully priced. Considering all these, though it sounds lucrative bet for the long term, risk savvy, cash surplus investors may consider investment at their own risk in this China connected IPO. Read detail review...
Related Articles
| Listing Date | November 20, 2020 |
| BSE Script Code | 543245 |
| NSE Symbol | GLAND |
| ISIN | INE068V01023 |
| Final Issue Price | ₹1500 per share |
| BSE Listing Group | B |
Gland Pharma Ltd.
Sy. No. 143 - 148, 150 and 151,
Near Gandi Maisamma 'X' Roads, D.P. Pally,Dundigal
Medchal-Malkajgiri District, Hyderabad
Hyderabad, Telangana
Phone: +91 40 3051 0999
Email: investors@glandpharma.com
Website: http://www.glandpharma.com
MUFG Intime India Pvt.Ltd.
Phone: +91-22-4918 6270
Email: glandpharma.ipo@linkintime.co.in
Website: https://linkintime.co.in/Initial_Offer/public-issues.html
Gland Pharma IPO is a main-board IPO of 4,31,96,968 equity shares of the face value of ₹1 aggregating up to ₹6,479.55 Crores. The issue is priced at ₹1500 per share. The minimum order quantity is 10.
The IPO opens on November 9, 2020, and closes on November 11, 2020.
MUFG Intime India Pvt.Ltd. is the registrar for the IPO. The shares are proposed to be listed on BSE, NSE.
Zerodha customers can apply online in Gland Pharma IPO using UPI as a payment gateway. Zerodha customers can apply in Gland Pharma IPO by login into Zerodha Console (back office) and submitting an IPO application form.
Steps to apply in Gland Pharma IPO through Zerodha
Visit Zerodha IPO Application Process Review for more detail.
The Gland Pharma IPO opens on November 9, 2020 and closes on November 11, 2020.
Gland Pharma IPO lot size is 10, and the minimum amount required for application is ₹15,000.
You can apply in Gland Pharma IPO online using either UPI or ASBA as a payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO Application is offered by brokers who don't offer banking services. Read more detail about applying IPO online through Zerodha, Upstox, 5Paisa, Nuvama, HDFC Bank, and SBI Bank.
The finalization of Basis of Allotment for Gland Pharma IPO will be done on Tuesday, November 17, 2020, and the allotted shares will be credited to your demat account by Thursday, November 19, 2020. Check the Gland Pharma IPO allotment status.
The Gland Pharma IPO listing date is on Friday, November 20, 2020.
Useful Articles
RHP